BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Costales C, Lin J, Kimoto E, Yamazaki S, Gosset JR, Rodrigues AD, Lazzaro S, West MA, West M, Varma MVS. Quantitative prediction of breast cancer resistant protein mediated drug-drug interactions using physiologically-based pharmacokinetic modeling. CPT Pharmacometrics Syst Pharmacol 2021. [PMID: 34164937 DOI: 10.1002/psp4.12672] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Moreira FL, Melli PPDS, Marques MP, Rocha A, Nardotto GHB, Duarte G, Lanchote VL. P-Glycoprotein and Organic Anion Transporter Polypeptide 1B/Breast Cancer Resistance Protein Drug Transporter Activity in Pregnant Women Living With HIV. J Clin Pharmacol 2023;63:219-27. [PMID: 36087110 DOI: 10.1002/jcph.2152] [Reference Citation Analysis]
2 Lin J, Kimoto E, Yamazaki S, Vourvahis M, Bergman A, Rodrigues AD, Costales C, Li R, Varma MVS. Effect of Hepatic Impairment on OATP1B Activity: Quantitative Pharmacokinetic Analysis of Endogenous Biomarker and Substrate Drugs. Clin Pharmacol Ther 2022. [PMID: 36524426 DOI: 10.1002/cpt.2829] [Reference Citation Analysis]
3 Heinig R, Fricke R, Wertz S, Nagelschmitz J, Loewen S. Results From Drug-Drug Interaction Studies In Vitro and In Vivo Investigating the Inhibitory Effect of Finerenone on the Drug Transporters BCRP, OATP1B1, and OATP1B3. Eur J Drug Metab Pharmacokinet 2022. [PMID: 36029368 DOI: 10.1007/s13318-022-00794-5] [Reference Citation Analysis]
4 Yang X, Reynolds K, Madabushi R, Huang SM. Current Perspective on Residual Knowledge Gaps in the Assessment of Transporter-Mediated Drug Interactions. Clin Pharmacol Ther 2022. [PMID: 35722741 DOI: 10.1002/cpt.2671] [Reference Citation Analysis]
5 Takubo H, Bessho K, Watari R, Shigemi R. Quantitative prediction of OATP1B-mediated drug-drug interactions using endogenous biomarker coproporphyrin I. Xenobiotica 2022;:1-26. [PMID: 35638858 DOI: 10.1080/00498254.2022.2085210] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Tess DA, Kimoto E, King-Ahmad A, Vourvahis M, Rodrigues AD, Bergman A, Qui R, Somayaji V, Weng Y, Fonseca KR, Litchfield J, Varma MVS. Effect of a Ketohexokinase Inhibitor (PF-06835919) on In Vivo OATP1B Activity: Integrative Risk Assessment Using Endogenous Biomarker and a Probe Drug. Clin Pharmacol Ther 2022. [PMID: 35355249 DOI: 10.1002/cpt.2593] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
7 Vourvahis M, Byon W, Chang C, Le V, Diehl A, Graham D, Tripathy S, Raha N, Luo L, Mathialagan S, Dowty M, Rodrigues AD, Malhotra B. Evaluation of the Effect of Abrocitinib on Drug Transporters by Integrated Use of Probe Drugs and Endogenous Biomarkers. Clin Pharmacol Ther 2022. [PMID: 35344588 DOI: 10.1002/cpt.2594] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Cheng Y, Wang X, Tong Z, Reyes J, Carayannopoulos L, Zhou S, Li Y. Assessment of Transporter-Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients With Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. J Clin Pharmacol 2021. [PMID: 34617279 DOI: 10.1002/jcph.1979] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]